ResearchSpace

Assessing a sustainable manufacturing route to lapatinib

Show simple item record

dc.contributor.author Stark, RT
dc.contributor.author Rye, DR
dc.contributor.author Newton, OJ
dc.contributor.author Deadman, BJ
dc.contributor.author Miller, PW
dc.contributor.author Panayides, Jenny-Lee
dc.contributor.author Riley, Darren L
dc.contributor.author Helldardt, K
dc.contributor.author Hii, KK
dc.date.accessioned 2023-03-17T09:30:54Z
dc.date.available 2023-03-17T09:30:54Z
dc.date.issued 2022-08
dc.identifier.citation Stark, R., Rye, D., Newton, O., Deadman, B., Miller, P., Panayides, J., Riley, D.L. & Helldardt, K. et al. 2022. Assessing a sustainable manufacturing route to lapatinib. <i>Reaction Chemistry & Engineering, 7.</i> http://hdl.handle.net/10204/12682 en_ZA
dc.identifier.issn 2058-9883
dc.identifier.uri DOI https://doi.org/10.1039/D2RE00267A
dc.identifier.uri http://hdl.handle.net/10204/12682
dc.description.abstract A synthetic route to an anti-cancer drug, lapatinib, was devised to support the development of a sustainable manufacturing process in South Africa. Quantitative metrics were employed to evaluate the sustainability of the key steps of the reaction. en_US
dc.format Fulltext en_US
dc.language.iso en en_US
dc.relation.uri https://pubs.rsc.org/en/content/articlelanding/2022/re/d2re00267a en_US
dc.source Reaction Chemistry & Engineering, 7 en_US
dc.subject Breast cancer en_US
dc.subject Risk factors en_US
dc.subject BRCA1 genes en_US
dc.subject BRCA2 genes en_US
dc.title Assessing a sustainable manufacturing route to lapatinib en_US
dc.type Article en_US
dc.description.pages 2420-2426 en_US
dc.description.note Open Access Article. This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. en_US
dc.description.cluster Chemicals en_US
dc.description.impactarea Pharmaceutical Technologies en_US
dc.identifier.apacitation Stark, R., Rye, D., Newton, O., Deadman, B., Miller, P., Panayides, J., ... Hii, K. (2022). Assessing a sustainable manufacturing route to lapatinib. <i>Reaction Chemistry & Engineering, 7</i>, http://hdl.handle.net/10204/12682 en_ZA
dc.identifier.chicagocitation Stark, RT, DR Rye, OJ Newton, BJ Deadman, PW Miller, Jenny-Lee Panayides, Darren L Riley, K Helldardt, and KK Hii "Assessing a sustainable manufacturing route to lapatinib." <i>Reaction Chemistry & Engineering, 7</i> (2022) http://hdl.handle.net/10204/12682 en_ZA
dc.identifier.vancouvercitation Stark R, Rye D, Newton O, Deadman B, Miller P, Panayides J, et al. Assessing a sustainable manufacturing route to lapatinib. Reaction Chemistry & Engineering, 7. 2022; http://hdl.handle.net/10204/12682. en_ZA
dc.identifier.ris TY - Article AU - Stark, RT AU - Rye, DR AU - Newton, OJ AU - Deadman, BJ AU - Miller, PW AU - Panayides, Jenny-Lee AU - Riley, Darren L AU - Helldardt, K AU - Hii, KK AB - A synthetic route to an anti-cancer drug, lapatinib, was devised to support the development of a sustainable manufacturing process in South Africa. Quantitative metrics were employed to evaluate the sustainability of the key steps of the reaction. DA - 2022-08 DB - ResearchSpace DP - CSIR J1 - Reaction Chemistry & Engineering, 7 KW - Breast cancer KW - Risk factors KW - BRCA1 genes KW - BRCA2 genes LK - https://researchspace.csir.co.za PY - 2022 SM - 2058-9883 T1 - Assessing a sustainable manufacturing route to lapatinib TI - Assessing a sustainable manufacturing route to lapatinib UR - http://hdl.handle.net/10204/12682 ER - en_ZA
dc.identifier.worklist 26614 en_US


Files in this item

Thumbnail
Name: RS_26614_Assessing ...
Size: 397.3Kb
Format: PDF
Description: Article
View/Open

This item appears in the following Collection(s)

Show simple item record